



SD BIOLINE HIV/SYPHILIS DUO

SAME-DAY TEST & TREATMENT



CURRENT PROBLEMS WITH SYPHILIS TESTING



THE CHALLENGES

- No ability to test and treat same day
- Requires electricity, instruments, laboratory equipment etc.
- HIV cannot be tested at the same time
- Waiting to take two tests in different sites
- Collecting blood twice
- Patient has to revisit hospital for results
- Heavy workload
- Hard to access antenatal clinic (ANC) services: walking >1 hour

MEAN DISTANCE TO THE NEAREST HEALTH FACILITY ¹



Adapted from: 1. World Health Organization (WHO)/TDR. The use of Rapid Syphilis Tests



BENEFITS OF SD BIOLINE HIV/SYPHILIS DUO TEST

PATIENTS

- Convenience of one sample
- Reduces time for testing
- Same day Test & Treatment
- Enables immediate partner notification

CLINICIANS

- Reduces workload
- Reduces training time
- Single procedure, two results

PROGRAM MANAGERS

- No instruments, electricity or laboratory equipment required
- Increasing test coverage
- Cost-effective by reducing cost of storage, logistics, local distribution
- Contributes to SDG

PERFORMANCE ²

The sensitivity and specificity of the SD BIOLINE HIV/Syphilis Duo test was consistently high across specimens from 6 countries around the world and it should be considered for improved HIV and syphilis screening coverage.

	DETECTION OF HIV ANTIBODIES		DETECTION OF TREPONEMA PALLIDUM ANTIBODIES	
Country	Sensitivity Estimate (exact 95% CI)	Specificity Estimate (exact 95% CI)	Sensitivity Estimate (exact 95% CI)	Specificity Estimate (exact 95% CI)
Ghana	100% (98.54%, 100%)	100% (97.57%, 100%)	100% (98.54%, 100%)	99.33% (96.34%, 99.98%)
Togo	100% (98.20%, 100%)	100% (96.61%, 100%)	100% (95.89%, 100%)	99.35% (96.41%, 99.98%)
Myanmar	100% (96.82%, 100%)	99.24% (95.82%, 99.98%)	98.67% (92.79%, 99.97%)	99.20% (95.62%, 99.98%)
Kenya	99.71% (98.40%, 99.99%)	100% (98.96%, 100%)	100% (95.75%, 100%)	100% (99.40%, 100%)
Mexico	100% (97.69%, 100%)	100% (99.01%, 100%)	99.07% (94.90%, 99.98%)	99.67% (98.20%, 99.99%)
Laos	100% (93.28%, 100%)	97.09% (91.72%, 99.40%)	100% (54.07%, 100%)	100% (96.38%, 100%)
TOTAL	99.91% (99.51%, 100%)	99.67% (99.16%, 99.91%)	99.67% (98.82%, 99.96%)	99.72% (99.29%, 99.92%)

COST EFFECTIVENESS³

The dual point-of-care screening algorithm had lower overall costs and decreased life-time disability when compared to the other screening choices.

	Total Costs	Cost increase from no program	DALYs	DALYs prevented compared to no program	CER comparing screening to no program	ICER*
No program	\$20,783,454	-	269,400	-	-	-
Dual HIV/syphilis	\$21,274,678	\$491,224	228,829	40,571	12.11	12.11
HIV test only	\$21,583,611	\$800,158	235,716	33,684	23.75	Strictly** dominated
Single rapid tests for HIV & syphilis	\$21,593,145	\$809,692	235,023	34,377	23.55	Strictly** dominated
HIV rapid test & RPR/TPPA for syphilis	\$21,605,356	\$821,902	235,094	34,306	23.96	Strictly** dominated

* Incremental cost effectiveness ratio (ICER) is the ratio of the change in costs to incremental benefit of an algorithm
 ** If an algorithm is both more costly and less effective than another algorithm it is considered "strictly dominated" and would not be recommended
 IA : Induced abortion DALY : Disability-adjusted life years CER : Cost-effectiveness ratio ICER : Incremental cost-effectiveness ratio

ACCEPTANCE STUDY⁴


Background (Maternity Hospital and Ventanilla-Callao, Peru)

- This study was carried out to evaluate the acceptability among ANC service providers.
- There were problems using separate HIV and Syphilis rapid tests from technicians:
 - Confusion with reagent and results
 - Stock outs of HIV test
- SD BIOLINE HIV/Syphilis Duo tests were provided to 10 ANC health centers

Results

- 100% reported satisfaction with SD BIOLINE HIV/Syphilis Duo test
- 100% considered the SD BIOLINE HIV/Syphilis Duo test to be better than separate tests
- 32% mentioned difficulties with reading results (now printed 'HIV' and 'SYP' below the test lines)

ACCEPTANCE SURVEY



Adapted from: Acceptance of HIV/Syphilis Duo Rapid Testing: Survey of Attitudes of Antenatal Care Providers in Peru

MAXIMIZE PMTCT SERVICE WITH HIV+SYPHILIS DUO

SIMPLE | RAPID | ACCURATE



RESULTS IN
15-20 MINUTES



SERUM, PLASMA,
WHOLE BLOOD



1-30°C
24 MONTHS



ORDER INFORMATION

Cat. No.	06FK30	06FK35
Specimen	S / P / WB	S / P / WB
Type	Device	Device
Pack Size	25T/Kit	25T/Kit
Dimension	177 x 110 x 75 mm	177 x 110 x 75 mm
Weight	250G	300G
Contents	Devices, Diluent	Devices, Diluent, Capillary Pipettes, Alcohol Swabs, Lancets
Carton	565 x 415 x 395mm (55Kits)	565 x 415 x 395mm (55Kits)
Certification	CE Marked (06FK30CE, 06FK35CE)	

References

- ¹ World Health Organization (WHO)/TDR. (2006) The use of Rapid Syphilis Tests. [Online] Available at: http://www.who.int/reproductivehealth/publications/rtis/TDR_SDL_06_1/en/ Accessed 28 Aug 2015.
- ² Bristow, C.C. et al. (2014) Multisite Laboratory Evaluation of a Dual Human Immunodeficiency Virus (HIV)/Syphilis Point-of-Care Rapid Test for Simultaneous Detection of HIV and Syphilis Infection. *Open Forum Infect Dis.* 1(1).
- ³ UCLA Program in Global Health, Klausner, J. (2014) Dual rapid tests are costeffective to prevent mother-to-child transmission of HIV infection, syphilis and adverse pregnancy outcomes. [Online] Available at: <http://www.dualelimination.org/#!cost-effectiveness/cnqx> Accessed 28 Aug 2015.
- ⁴ Acceptance of HIV/Syphilis Duo Rapid Testing: Survey of Attitudes of Antenatal Care Providers in Peru by Maria Valderrama MSH. [Online] <https://cdc.confex.com/cdc/std2014/webprogram/Paper34834.html>

© 2018 Abbott. All rights reserved. All trademarks referenced are trademarks of either the Abbott group of companies or their respective owners. Any photos displayed are for illustrative purposes only. Any person depicted in such photos is a model. 120002110-02 07/18

